Public Health Service Guidelines for the Management of Possible Sexual, Injecting-Drug-Use, or Other Nonoccupational Exposure to HIV, Including Considerations Related to Antiretroviral Therapy

Surveillance of Documented Exposures

CDC is initiating a surveillance system to collect information about persons who seek medical care after possible sexual, injecting-drug-use, or other nonoccupational HIV exposures. No names or other personal identifiers of patients will be collected. Health-care providers in the United States soon will be encouraged to report all persons who receive or who are considered for antiretroviral agents for nonoccupational HIV exposure to an anonymous registry that CDC is developing. The system will assess utilization, effectiveness, and medication toxicity for those who receive treatment through collection of the following information:

• characteristics of the reported exposure;

• use of antiretroviral medications, including dosage and duration;
  Advertisement

• toxicity of and adherence to therapy;

• HIV seroconversion in patients who do and do not receive antiretroviral therapy after exposure to a known HIV-infected source.

CDC will request follow-up information on patients whose nonoccupational HIV exposure is documented and who gave consent to their physician for data reporting. CDC also will assist with HIV testing when asked.

Unusual or severe toxicity from antiretroviral drugs should be reported to the manufacturer or the Food and Drug Administration ([800]-332-1088). The use of antiretroviral drugs for pregnant women should be reported (without patient identifiers) to the Antiretroviral Pregnancy Registry ([800]-258-4263).

For further information about the CDC-sponsored External Consultants Meeting on Antiretroviral Therapy for Potential Nonoccupational Exposures to HIV, which took place in July, 1997, contact the National AIDS Clearinghouse ([800]-458-5231 or the Internet website.